Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation

European Journal of Clinical Pharmacology

Volumn 72, Issue 3, 2016, Pages 329-338

  Forslund, Tomas ^a,b   Wettermark, Björn ^a,b   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Adherence; Anticoagulant; Antithrombotic; Atrial fibrillation; NOAC; Persistence

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CHADS2 SCORE; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; VERY ELDERLY; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DABIGATRAN; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PYRAZOLES; PYRIDONES; RIVAROXABAN; WARFARIN;

EID: 84958124610     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1983-z     Document Type: Article

References (35)

1. Friberg L, Bergfeldt L (2013) Atrial fibrillation prevalence revisited. Intern Med 274:461-468
2. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2014) Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: Experience from the Stockholm region. Eur J Clin Pharmacol 70:1477-1485
3. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857-867
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. (2009) (For the RE-LY investigators): Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
5. Patel MR, Mahaffey KW, Garg J, et al. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 8(365):883-891
6. Granger CB, Alexander JH, McMurray JJ, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
7. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P (2013) Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system. Int J Cardiol 170:208-214
8. Camm AJ, Lip GY (2012) De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG); 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-2747
9. Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D (2014) Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 89:896-907
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817
11. Eichler HG, Abadie E, Breckenridge A, et al. (2011) Bridging the efficacy-effectiveness gap: A regulator's perspective on addressing variability of drug response. Nat Review Drug Discov. 10:495-506
12. Skeppholm M, Friberg L (2014) Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 103:998-1005
13. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G (2014) Prognosis and treatment of atrial fibrillation patients by European cardiologists: One year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 35:3365-3376
14. Song X, Sander SD, Varker H, Amin A (2012) Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 12:245-253
15. Gallagher AM, Rietbrock S, Plumb J, van Staa TP (2008) Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: Do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6:1500-1506
16. Suh DC, Choi JC, Schein J, Kim S, Nelson WW (2013) Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. Curr Med Res Opin 29:761-771
17. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6:567-574
18. Beyer-Westendorf J, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost 113:1247-1257
19. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Barón AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans health administration. Am Heart J 167:810-817
20. Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F, Longo L, Jackevicius C, Rose A, Turakhia MP (2015) Site-level variation in and practices associated with dabigatran adherence. J Am Med Assoc 313:1443-1450
21. Beyer-Westendorf J, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, Michalski F, Endig H, Sahin K, Tittl L, Weiss N (2015) Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 17:530-538
22. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, Schein JR (2014) Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 30:2461-2469
23. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P (2014) Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 30:1317-1325
24. Caetano PA, Lam JM, Morgan SG (2006) Toward a standard definition and measurement of persistence with drug therapy: Examples from research on statin and antihypertensive utilization. Clin Ther 28:1411-1424
25. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF (2013) Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 51:S11-S21
26. Friberg L, Skeppholm M, Terént A (2015) Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 65:225-232
27. Wettermark B, Hammar N, Fored M, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish prescribed drug register - Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726-735
28. January CT, Wann LS, Alpert JS, Calkins H, Cleveland Jr JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circ 130:2071-2104
29. Ben Freedman S, Gersh BJ, Lip GY (2015) Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J 36:653-656
30. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A (2015) Safety and efficacy of well managed warfarin. A report from the Swedish quality register auricula. Thromb Haemost 113:1370-1377
31. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM (2013) Fox KA; ROCKET AF investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: Data from the ROCKET AF clinical trial. J Am Heart Assoc 2:e000067
32. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC (2009) Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 15:e22-e33
33. Vrijens B, Heidbuchel H (2015) Non-vitamin K antagonist oral anticoagulants: Considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 17:514-523
34. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
35. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA (2011) Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development. Clin Pharmacol Ther 90:777-790